The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

HALOFENATE     2-acetamidoethyl 2-(4-chlorophenyl)-2-[3...

Synonyms: Halofenato, Halofenatum, CHEMBL456071, SureCN635325, MK-185, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of HALOFENATE


High impact information on HALOFENATE


Biological context of HALOFENATE


Associations of HALOFENATE with other chemical compounds


Gene context of HALOFENATE

  • The influence of Halofenate therapy on insulin and glucagon secretion was examined in the Zucker rat with genetic endogenous hyperlipemia [16].
  • Coincident with the lipid lowering effects of Halofenate, the net change in the basal bihormonal axis favored glucagon, with the I/G molar ratio (Insulin/Glucagon) decreasing from 2.72 +/- 0.53 to 0.96 +/- 0.20 during treatment with this drug [16].

Analytical, diagnostic and therapeutic context of HALOFENATE


  1. Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity. Allen, T., Zhang, F., Moodie, S.A., Clemens, L.E., Smith, A., Gregoire, F., Bell, A., Muscat, G.E., Gustafson, T.A. Diabetes (2006) [Pubmed]
  2. Halofenate. Its selection and trial as a primary uricosuric agent. Bluestone, R., Campion, D., Klinenberg, J.R. Arthritis Rheum. (1975) [Pubmed]
  3. Efficacy and interactions of oxandrolone, halo-fenate and clofibrate in a factorial study on experimental acute nephrotic hyperlipidemia. Schapel, G.J., Edwards, K.D. J. Pharmacol. Exp. Ther. (1975) [Pubmed]
  4. A two-year crossover therapeutic trial with halofenate and clofibrate. Dujovne, C.A., Azarnoff, D.L., Pentikainen, P., Manion, C., Hurwitz, A., Hassanein, K. Am. J. Med. Sci. (1976) [Pubmed]
  5. Halofenate: a potent inhibitor of normal and hypersensitive platelets. Colman, R.W., Bennett, J.S., Sheridan, J.F., Cooper, R.A., Shattil, S.J. J. Lab. Clin. Med. (1976) [Pubmed]
  6. Potentiation of hypoglycemic effect of sulfonylureas by halofenate. Jain, A.K., Ryan, J.R., McMahon, F.G. N. Engl. J. Med. (1975) [Pubmed]
  7. Changes in serum thyrotropin (TSH) in man during halofenate administration. Davis, P.J., Davis, F.B., Utiger, R.D., Kulaga, S.F. J. Clin. Endocrinol. Metab. (1976) [Pubmed]
  8. The interaction between halofenate and propranolol. Huffman, D.H., Azarnoff, D.L., Shoeman, D.W., Dujovne, C.A. Clin. Pharmacol. Ther. (1976) [Pubmed]
  9. Platelet function in hyperbetalipoproteinemia. Colman, R.W. Thromb. Haemost. (1978) [Pubmed]
  10. The effect of halofenate--free acid on aggregation--the release reaction, coagulant activity, and lipid metabolism of human platelets. Huzoor-Akbar, n.u.l.l., Ardlie, N.G. Thromb. Haemost. (1977) [Pubmed]
  11. Halofenate and clofibrate: mechanism of hypotriglyceridemic action in the rat. Cenedella, R.J., Crouthamel, W.G. J. Lipid Res. (1976) [Pubmed]
  12. Effects of halofenate on glucose tolerance in patients with hyperlipoproteinemia. Feldman, E.B., Gluck, F.B., Carter, A.C. Journal of clinical pharmacology. (1978) [Pubmed]
  13. Studies on the mechanism of action of halofenate. Mandel, L.R. Lipids (1977) [Pubmed]
  14. Determination of various drugs in rodent diet mixtures. Hucker, H.B., Stauffer, S.C. J. Chromatogr. (1977) [Pubmed]
  15. Anomalous results of studies on drug interaction in man. II. Halofenate (mk-185) and antipyrine, bishydroxycoumarin, and warfarin. Vesell, E.S., Passananti, G.T. Pharmacology (1975) [Pubmed]
  16. Altered insulin and glucagon secretion in treated genetic hyperlipemia: a mechanism of theraphy? Eaton, R.P., Oase, R., Schade, D.S. Metab. Clin. Exp. (1976) [Pubmed]
WikiGenes - Universities